BIOPHARMA
ByCan Amgen’s 2025 Approvals and Launches Strengthen Its Oncology, Cardiovascular, and Bone Health Leadership Into 2026?
Global | January 2026 — Amgen Inc. achieved key milestones in 2025, marked by multiple regulatory approvals, label…
Can GSK’s 2025 Approvals and Launches Strengthen Its Vaccines, Respiratory, and Immunology Leadership Into 2026?
Global | January 2026 — GlaxoSmithKline PLC (GSK) achieved key milestones in 2025, with multiple regulatory approvals, product…
Can AstraZeneca’s 2025 Launches and Approvals Strengthen Its Oncology, Cardiovascular, and Respiratory Leadership Into 2026?
Global | January 2026 — AstraZeneca PLC achieved significant milestones in 2025, marked by multiple regulatory approvals, label…
Can Novo Nordisk’s 2025 Diabetes, Obesity, and Rare Disease Launches Drive Sustainable Growth Into 2026?
Global | January 2026 — Novo Nordisk A/S continued to reinforce its leadership in diabetes, obesity, and rare…
FDA Grants Breakthrough Therapy Status to Lilly’s Folate Receptor-Targeted Ovarian Cancer Candidate
23 January 2026 Executive Summary Eli Lilly announced that the U.S. Food and Drug Administration (FDA) has granted…
Despite Geopolitical Tensions, U.S.–China Biotech Interdependence Remains Central
23 January 2026 Executive Summary Industry reports continue to underscore the deep interdependence between U.S. and Chinese biotech…
